 | Cougar Biotechnology, Inc. is a Los Angeles-based company with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, which is currently being tested in a Phase III clinical trial in prostate cancer and a Phase I/II trial in breast cancer; CB3304, which is currently in a Phase I trial in multiple myeloma; and CB1089, which has been clinically tested in a number of solid tumor types.
On July 10, 2009, Johnson & Johnson acquired Cougar. Click here for a link to the press release announcing the acquisition.
100% Anonymous feedback to
an independent third party.
| | |
|
|
